Regulatory 2026-04-09 | Annual Report 2025: Orviglance NDA submitted to the FDA, PDUFA-date set for July 2026 PDF Report Presentation Webcast
Regulatory 2026-03-30 | Notice of Annual General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
2026-03-27 | ASCELIA PHARMA ANNOUNCES ACCEPTANCE OF ORVIGLANCE DATA FOR ORAL PRESENTATION AT THE ANNUAL RADIOLOGY CONGRESS ESGAR 2026 PDF Report Presentation Webcast
Regulatory 2026-02-05 | Full Year and Q4 Report 2025: FDA Accepts Orviglance NDA for Review PDF Report Presentation Webcast
Regulatory 2026-01-21 | Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company PDF Report Presentation Webcast
Regulatory 2025-12-22 | Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-11-28 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-11-19 | Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program PDF Report Presentation Webcast
2025-11-15 | Ascelia Pharma Announces FDA Acceptance of Orviglance New Drug Application for Review PDF Report Presentation Webcast
2025-11-10 | Ascelia Pharma Files New Patent Application for Orviglance PDF Report Presentation Webcast
Regulatory 2025-11-05 | Quarterly Report Q3 2025: Orviglance NDA Submitted to the FDA PDF Report Presentation Webcast
Regulatory 2025-11-03 | Ascelia Pharma Announces Management Changes to Support Future Growth PDF Report Presentation Webcast
Regulatory 2025-09-30 | Change in Number of Shares and Votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2025-09-22 | Ascelia Pharma Has Completed a Directed Share Issue of Approximately SEK 30 Million PDF Report Presentation Webcast
Regulatory 2025-09-22 | Ascelia Pharma Intends to Carry Out a Directed Share Issue of Approximately SEK 30 Million PDF Report Presentation Webcast
2025-09-03 | Ascelia Pharma Submits Orviglance New Drug Application to the U.S. Food and Drug Administration PDF Report Presentation Webcast
Regulatory 2025-09-02 | Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a Total Nominal Amount of SEK 7.5 Million PDF Report Presentation Webcast
Regulatory 2025-08-21 | Half-Year Report 2025: Orviglance NDA Submission Approaching PDF Report Presentation Webcast
